Clinical Trial: Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: An Open-Label Safety And Blood Collection Study In Mnb Rlp2086 Vaccinated Healthy Adult Volunteers For Immunological Assay Development
Brief Summary: The purpose of this study is to evaluate the safety of an investigational meningococcal B rLP2086 vaccine in adults and to obtain blood samples from immunized subjects for use in assay development.
Detailed Summary:
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Current Primary Outcome: Safety of 3 doses of MnB rLP2086 vaccine candidate assessed by frequency of solicited local and systemic reactions collected for 7 days after each study vaccination; evaluation of occurrence of AE and SAE during the duration of study [ Time Frame: Up to 2 years ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Wyeth is now a wholly owned subsidiary of Pfizer
Dates:
Date Received: October 24, 2008
Date Started: October 2008
Date Completion:
Last Updated: August 22, 2011
Last Verified: August 2011